|
Access Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Access Pharmaceuticals, Inc.. The Group's principal activity is to develop drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and treatment of oral diseases. It is in the development stage. The Group has proprietary patents and rights to seven drug delivery technology platforms: synthetic polymer targeted delivery, vitamin mediated targeted delivery (including oral), bioerodible hydrogel technology, nanoparticles and nanoparticle networks, Residerm (R) topical delivery, carbohydrate targeting technology and agents for the prevention and treatment of viral disease, including HIV. The products Residerm (R) A gel - Zindaclin (TM), Aphthasol (R) and Aptheal (R) are being marketed currently. On 25-February-2009, the Group acquired MacroChem Corporation.
Competitor Analysis
This analysis compares Access Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
